Search

Your search keyword '"McMiller, Tracee L."' showing total 38 results
Start Over Author "McMiller, Tracee L."
38 results on '"McMiller, Tracee L."'

1. Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade

Author

Chen, Shuming, McMiller, Tracee L., Soni, Abha, Succaria, Farah, Sidhom, John-William, Cappelli, Laura C., Casciola-Rosen, Livia A., Morales, Isaac R., Sankaran, Preethi, Berger, Alan E., Deutsch, Julie Stein, Zhu, Qingfeng C., Anders, Robert A., Hooper, Jody E., Pardoll, Drew M., Lipson, Evan J., Taube, Janis M., and Topalian, Suzanne L.

Published
2024
Full Text
View/download PDF

5. Abstract 2260: Characterizing tumor stromal evolution after neoadjuvant anti-PD-1 therapy in Merkel cell carcinoma

Author

Sunshine, Joel C., primary, McMiller, Tracee L., additional, Skaist, Alyza, additional, Zhang, Yan, additional, Berger, Alan, additional, Schuebel, Kornel, additional, Meyers, Jennifer, additional, Deutsch, Julie S., additional, Ogurtsova, Aleksandra, additional, Engle, Elizabeth L., additional, Cope, Leslie, additional, Taube, Janis M., additional, and Topalian, Suzanne L., additional

Published
2023
Full Text
View/download PDF

7. Supplementary Figures S1 through S4 from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma

Author

Ascierto, Maria Libera, primary, McMiller, Tracee L., primary, Berger, Alan E., primary, Danilova, Ludmila, primary, Anders, Robert A., primary, Netto, George J., primary, Xu, Haiying, primary, Pritchard, Theresa S., primary, Fan, Jinshui, primary, Cheadle, Chris, primary, Cope, Leslie, primary, Drake, Charles G., primary, Pardoll, Drew M., primary, Taube, Janis M., primary, and Topalian, Suzanne L., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Tables S1 through S3 from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma

Author

Ascierto, Maria Libera, primary, McMiller, Tracee L., primary, Berger, Alan E., primary, Danilova, Ludmila, primary, Anders, Robert A., primary, Netto, George J., primary, Xu, Haiying, primary, Pritchard, Theresa S., primary, Fan, Jinshui, primary, Cheadle, Chris, primary, Cope, Leslie, primary, Drake, Charles G., primary, Pardoll, Drew M., primary, Taube, Janis M., primary, and Topalian, Suzanne L., primary

Published
2023
Full Text
View/download PDF

9. Data from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma

Author

Ascierto, Maria Libera, primary, McMiller, Tracee L., primary, Berger, Alan E., primary, Danilova, Ludmila, primary, Anders, Robert A., primary, Netto, George J., primary, Xu, Haiying, primary, Pritchard, Theresa S., primary, Fan, Jinshui, primary, Cheadle, Chris, primary, Cope, Leslie, primary, Drake, Charles G., primary, Pardoll, Drew M., primary, Taube, Janis M., primary, and Topalian, Suzanne L., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Materials and Methods from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma

Author

Ascierto, Maria Libera, primary, McMiller, Tracee L., primary, Berger, Alan E., primary, Danilova, Ludmila, primary, Anders, Robert A., primary, Netto, George J., primary, Xu, Haiying, primary, Pritchard, Theresa S., primary, Fan, Jinshui, primary, Cheadle, Chris, primary, Cope, Leslie, primary, Drake, Charles G., primary, Pardoll, Drew M., primary, Taube, Janis M., primary, and Topalian, Suzanne L., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figures 1 - 3 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

Author

Taube, Janis M., primary, Young, Geoffrey D., primary, McMiller, Tracee L., primary, Chen, Shuming, primary, Salas, January T., primary, Pritchard, Theresa S., primary, Xu, Haiying, primary, Meeker, Alan K., primary, Fan, Jinshui, primary, Cheadle, Chris, primary, Berger, Alan E., primary, Pardoll, Drew M., primary, and Topalian, Suzanne L., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figures S1, S2A, S2B, S3, S4A, S4B from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy

Author

Ascierto, Maria L., primary, Makohon-Moore, Alvin, primary, Lipson, Evan J., primary, Taube, Janis M., primary, McMiller, Tracee L., primary, Berger, Alan E., primary, Fan, Jinshui, primary, Kaunitz, Genevieve J., primary, Cottrell, Tricia R., primary, Kohutek, Zachary A., primary, Favorov, Alexander, primary, Makarov, Vladimir, primary, Riaz, Nadeem, primary, Chan, Timothy A., primary, Cope, Leslie, primary, Hruban, Ralph H., primary, Pardoll, Drew M., primary, Taylor, Barry S., primary, Solit, David B., primary, Iacobuzio-Donahue, Christine A., primary, and Topalian, Suzanne L., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Methods from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy

Author

Ascierto, Maria L., primary, Makohon-Moore, Alvin, primary, Lipson, Evan J., primary, Taube, Janis M., primary, McMiller, Tracee L., primary, Berger, Alan E., primary, Fan, Jinshui, primary, Kaunitz, Genevieve J., primary, Cottrell, Tricia R., primary, Kohutek, Zachary A., primary, Favorov, Alexander, primary, Makarov, Vladimir, primary, Riaz, Nadeem, primary, Chan, Timothy A., primary, Cope, Leslie, primary, Hruban, Ralph H., primary, Pardoll, Drew M., primary, Taylor, Barry S., primary, Solit, David B., primary, Iacobuzio-Donahue, Christine A., primary, and Topalian, Suzanne L., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Table S1 from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy

Author

Ascierto, Maria L., primary, Makohon-Moore, Alvin, primary, Lipson, Evan J., primary, Taube, Janis M., primary, McMiller, Tracee L., primary, Berger, Alan E., primary, Fan, Jinshui, primary, Kaunitz, Genevieve J., primary, Cottrell, Tricia R., primary, Kohutek, Zachary A., primary, Favorov, Alexander, primary, Makarov, Vladimir, primary, Riaz, Nadeem, primary, Chan, Timothy A., primary, Cope, Leslie, primary, Hruban, Ralph H., primary, Pardoll, Drew M., primary, Taylor, Barry S., primary, Solit, David B., primary, Iacobuzio-Donahue, Christine A., primary, and Topalian, Suzanne L., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table S1, Supplementary Table S3, Supplementary Table S5 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

Author

Taube, Janis M., primary, Young, Geoffrey D., primary, McMiller, Tracee L., primary, Chen, Shuming, primary, Salas, January T., primary, Pritchard, Theresa S., primary, Xu, Haiying, primary, Meeker, Alan K., primary, Fan, Jinshui, primary, Cheadle, Chris, primary, Berger, Alan E., primary, Pardoll, Drew M., primary, and Topalian, Suzanne L., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table S4 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

Author

Taube, Janis M., primary, Young, Geoffrey D., primary, McMiller, Tracee L., primary, Chen, Shuming, primary, Salas, January T., primary, Pritchard, Theresa S., primary, Xu, Haiying, primary, Meeker, Alan K., primary, Fan, Jinshui, primary, Cheadle, Chris, primary, Berger, Alan E., primary, Pardoll, Drew M., primary, and Topalian, Suzanne L., primary

Published
2023
Full Text
View/download PDF

17. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Author

Brahmer, Julie R., primary, Drake, Charles G., additional, Wollner, Ira, additional, Powderly, John D., additional, Picus, Joel, additional, Sharfman, William H., additional, Stankevich, Elizabeth, additional, Pons, Alice, additional, Salay, Theresa M., additional, McMiller, Tracee L., additional, Gilson, Marta M., additional, Wang, Changyu, additional, Selby, Mark, additional, Taube, Janis M., additional, Anders, Robert, additional, Chen, Lieping, additional, Korman, Alan J., additional, Pardoll, Drew M., additional, Lowy, Israel, additional, and Topalian, Suzanne L., additional

Published
2023
Full Text
View/download PDF

20. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Author

Topalian, Suzanne L., Hodi, F. Stephen, Brahmer, Julie R., Gettinger, Scott N., Smith, David C., McDermott, David F., Powderly, John D., Carvajal, Richard D., Sosman, Jeffrey A., Atkins, Michael B., Leming, Philip D., Spigel, David R., Antonia, Scott J., Horn, Leora, Drake, Charles G., Pardoll, Drew M., Chen, Lieping, Sharfman, William H., Anders, Robert A., Taube, Janis M., McMiller, Tracee L., Xu, Haiying, Korman, Alan J., Jure-Kunkel, Maria, Agrawal, Shruti, McDonald, Daniel, Kollia, Georgia D., Gupta, Ashok, Wigginton, Jon M., and Sznol, Mario

Published
2012
Full Text
View/download PDF

21. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas

Author

Succaria, Farah, primary, Kvistborg, Pia, additional, Stein, Julie E., additional, Engle, Elizabeth L., additional, McMiller, Tracee L., additional, Rooper, Lisa M., additional, Thompson, Elizabeth, additional, Berger, Alan E., additional, van den Brekel, Michiel, additional, Zuur, Charlotte L., additional, Haanen, John, additional, Topalian, Suzanne L., additional, and Taube, Janis M., additional

Published
2020
Full Text
View/download PDF

23. Abstract 4750: The immunosuppressive tumor microenvironment (TME) in nasopharyngeal carcinoma: implications for immunotherapy

Author

Duffield, Amy S., primary, Ascierto, Maria Libera, additional, Anders, Robert A., additional, Taube, Janis M., additional, McMiller, Tracee L., additional, Engle, Elizabeth L., additional, Meeker, Alan K., additional, Berger, Alan E., additional, Pardoll, Drew M., additional, Ambinder, Richard F., additional, and Topalian, Suzanne L., additional

Published
2018
Full Text
View/download PDF

24. Melanoma and immunotherapy bridge 2015

Author

Nanda, Vashisht G. Y., Peng, Weiyi, Hwu, Patrick, Davies, Michael A., Ciliberto, Gennaro, Fattore, Luigi, Malpicci, Debora, Aurisicchio, Luigi, Ascierto, Paolo Antonio, Croce, Carlo M., Mancini, Rita, Spranger, Stefani, Gajewski, Thomas F., Wang, Yangyang, Ferrone, Soldano, Vanpouille-Box, Claire, Wennerberg, Erik, Pilones, Karsten A., Formenti, Silvia C., Demaria, Sandra, Tang, Haidong, Wang, Yang, Fu, Yang-Xin, Dummer, Reinhard, Puzanov, Igor, Tarhini, Ahmad, Chauvin, Joe-Marc, Pagliano, Ornella, Fourcade, Julien, Sun, Zhaojun, Wang, Hong, Sanders, Cindy, Kirkwood, John M., Chen, Tseng-hui Timothy, Maurer, Mark, Korman, Alan J., Zarour, Hassane M., Stroncek, David F., Huber, Veronica, Rivoltini, Licia, Thurin, Magdalena, Rau, Tilman, Lugli, Alessandro, Pagès, Franck, Camarero, Jorge, Sancho, Arantxa, Jommi, Claudio, de Coaña, Yago Pico, Wolodarski, Maria, Yoshimoto, Yuya, Gentilcore, Giusy, Poschke, Isabel, Masucci, Giuseppe V., Hansson, Johan, Kiessling, Rolf, Scognamiglio, Giosuè, Sabbatino, Francesco, Marino, Federica Zito, Anniciello, Anna Maria, Cantile, Monica, Cerrone, Margherita, Scala, Stefania, D’alterio, Crescenzo, Ianaro, Angela, Cirin, Giuseppe, Liguori, Giuseppina, Bott, Gerardo, Chapman, Paul B., Robert, Caroline, Larkin, James, Haanen, John B., Ribas, Antoni, Hogg, David, Hamid, Omid, Testori, Alessandro, Lorigan, Paul, Sosman, Jeffrey A., Flaherty, Keith T., Yue, Huibin, Coleman, Shelley, Caro, Ivor, Hauschild, Axel, McArthur, Grant A., Sznol, Mario, Callahan, Margaret K., Kluger, Harriet, Postow, Michael A., Gordan, RuthAnn, Segal, Neil H., Rizvi, Naiyer A., Lesokhin, Alexander, Atkins, Michael B., Burke, Matthew M., Ralabate, Amanda, Rivera, Angel, Kronenberg, Stephanie A., Agunwamba, Blessing, Ruisi, Mary, Horak, Christine, Jiang, Joel, Wolchok, Jedd, Ascierto, Paolo A., Liszkay, Gabriella, Maio, Michele, Mandalà, Mario, Demidov, Lev, Stoyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Wongchenko, Matthew, Chang, Ilsung, Koralek, Daniel O., Rooney, Isabelle, Yan, Yibing, Dréno, Brigitte, Sullivan, Ryan, Patel, Manish, Hodi, Stephen, Amaria, Rodabe, Boasberg, Peter, Wallin, Jeffrey, He, Xian, Cha, Edward, Richie, Nicole, Ballinger, Marcus, Smith, David C., Bauer, Todd M., Wasser, Jeffrey S., Luke, Jason J., Balmanoukian, Ani S., Kaufman, David R., Zhao, Yufan, Maleski, Janet, Leopold, Lance, Gangadhar, Tara C., Long, Georgina V., Michielin, Olivier, VanderWalde, Ari, Andtbacka, Robert H. I., Cebon, Jonathan, Fernandez, Eugenio, Malvehy, Josep, Olszanski, Anthony J., Gause, Christine, Chen, Lisa, Chou, Jeffrey, Stephen Hodi, F., Brady, Benjamin, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Lebbé, Celeste, Ny, Lars, Chacon, Matias, Queirolo, Paola, Loquai, Carmen, Cheema, Parneet, Berrocal, Alfonso, Eizmendi, Karmele Mujika, Bar-Sela, Gil, Hardy, Helene, Weber, Jeffrey S., Grob, Jean-Jacques, Marquez-Rodas, Ivan, Schmidt, Henrik, Briscoe, Karen, Baurain, Jean-François, Wolchok, Jedd D., Pinto, Rosamaria, De Summa, Simona, Garrisi, Vito Michele, Strippoli, Sabino, Azzariti, Amalia, Guida, Gabriella, Guida, Michele, Tommasi, Stefania, Jacquelot, Nicolas, Enot, David, Flament, Caroline, Pitt, Jonathan M., Vimond, Nadège, Blattner, Carolin, Yamazaki, Takahiro, Roberti, Maria-Paula, Vetizou, Marie, Daillere, Romain, Poirier-Colame, Vichnou, la Semeraro, Michaë, Caignard, Anne, Slingluff, Craig L, Sallusto, Federica, Rusakiewicz, Sylvie, Weide, Benjamin, Marabelle, Aurélien, Kohrt, Holbrook, Dalle, Stéphane, Cavalcanti, Andréa, Kroemer, Guido, Di Giacomo, Anna Maria, Maio, Michaele, Wong, Phillip, Yuan, Jianda, Umansky, Viktor, Eggermont, Alexander, Zitvogel, Laurence, Anna, Passarelli, Marco, Tucci, Stefania, Stucci, Francesco, Mannavola, Mariaelena, Capone, Gabriele, Madonna, Antonio, Ascierto Paolo, Franco, Silvestris, Roberti, María Paula, Enot, David P., Semeraro, Michaela, Jégou, Sarah, Flores, Camila, Kwon, Byoung S., Anderson, Ana Carrizossa, Borg, Christophe, Aubin, François, Ayyoub, Maha, De Presbiteris, Anna Lisa, Cordaro, Fabiola Gilda, Camerlingo, Rosa, Fratangelo, Federica, Mozzillo, Nicola, Pirozzi, Giuseppe, Patriarca, Eduardo J., Caputo, Emilia, Motti, Maria Letizia, Falcon, Rosaria, Miceli, Roberta, Capone, Mariaelena, Madonna, Gabriele, Mallardo, Domenico, Carrier, Maria Vincenza, Panza, Elisabetta, De Cicco, Paola, Armogida, Chiara, Ercolano, Giuseppe, Botti, Gerardo, Cirino, Giuseppe, Sandru, Angela, Blank, Miri, Balatoni, Timea, Olasz, Judit, Farkas, Emil, Szollar, Andras, Savolt, Akos, Godeny, Maria, Csuka, Orsolya, Horvath, Szabolcs, Eles, Klara, Shoenfeld, Yehuda, Kasler, Miklos, Costantini, Susan, Capone, Francesca, Moradi, Farnaz, Berglund, Pontus, Leandersson, Karin, Linnskog, Rickard, Andersson, Tommy, Prasad, Chandra Prakash, Nigro, Cristiana Lo, Lattanzio, Laura, Wang, Hexiao, Proby, Charlotte, Syed, Nelofer, Occelli, Marcella, Cauchi, Carolina, Merlano, Marco, Harwood, Catherine, Thompson, Alastair, Crook, Tim, Bifulco, Katia, Ingangi, Vincenzo, Minopoli, Michele, Ragone, Concetta, Pessi, Antonello, Mannavola, Francesco, D’Oronzo, Stella, Felici, Claudia, Tucci, Marco, Doronzo, Antonio, Silvestris, Franco, Ferretta, Anna, Guida, Stefania, Maida, Imma, Cocco, Tiziana, Passarelli, Anna, Quaresmini, Davide, Franzese, Ornella, Palermo, Belinda, Di Donna, Cosmo, Sperduti, Isabella, Foddai, MariaLaura, Stabile, Helena, Gismondi, Angela, Santoni, Angela, Nisticò, Paola, Sponghini, Andrea P., Platini, Francesca, Marra, Elena, Rondonotti, David, Alabiso, Oscar, Fierro, Maria T., Savoia, Paola, Stratica, Florian, Quaglino, Pietro, Di Monta, Gianluca, Corrado, Caracò, Di Marzo, Massimiliano, Ugo, Marone, Di Cecilia, Maria Luisa, Nicola, Mozzillo, Fusciello, Celeste, Marra, Antonio, Guarrasi, Rosario, Baldi, Carlo, Russo, Rosa, Di Giulio, Giovanni, Faiola, Vincenzo, Zeppa, Pio, Pepe, Stefano, Gambale, Elisabetta, Carella, Consiglia, Di Paolo, Alessandra, De Tursi, Michele, Marra, Laura, De Murtas, Fara, Sorrentino, Valeria, Voinea, Silviu, Panaitescu, Eugenia, Bolovan, Madalina, Stanciu, Adina, Cinca, Sabin, Botti, Chiara, Aquino, Gabriella, Anniciello, Annamaria, Fortes, Cristina, Mastroeni, Simona, Caggiati, Alessio, Passarelli, Francesca, Zappalà, Alba, Capuano, Maria, Bono, Riccardo, Nudo, Maurizio, Marino, Claudia, Michelozzi, Paola, De Biasio, Valeria, Battarra, Vincenzo C., Formenti, Silvia, Ascierto, Maria Libera, McMiller, Tracee L., Berger, Alan E., Danilova, Ludmila, Anders, Robert A., Netto, George J., Xu, Haiying, Pritchard, Theresa S., Fan, Jinshui, Cheadle, Chris, Cope, Leslie, Drake, Charles G., Pardoll, Drew M., Taube, Janis M., Topalian, Suzanne L., Gnjatic, Sacha, Nataraj, Sarah, Imai, Naoko, Rahman, Adeeb, Jungbluth, Achim A., Pan, Linda, Venhaus, Ralph, Park, Andrew, Lehmann, Frédéric F., Lendvai, Nikoletta, Cohen, Adam D., Cho, Hearn J., Daniel, Speiser, and Hirsh, Vera

Subjects
Medicine(all), Biochemistry, Genetics and Molecular Biology(all), Meeting Abstracts
Abstract

Table of contents MELANOMA BRIDGE 2015 KEYNOTE SPEAKER PRESENTATIONS Molecular and immuno-advances K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies K2 Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistance Gennaro Ciliberto, Luigi Fattore, Debora Malpicci, Luigi Aurisicchio, Paolo Antonio Ascierto, Carlo M. Croce, Rita Mancini K3 Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidance Stefani Spranger, Thomas F. Gajewski K4 Intracellular tumor antigens as a source of targets of antibody-based immunotherapy of melanoma Yangyang Wang, Soldano Ferrone Combination therapies K5 Harnessing radiotherapy to improve responses to immunotherapy in cancer Claire Vanpouille-Box, Erik Wennerberg, Karsten A. Pilones, Silvia C. Formenti, Sandra Demaria K6 Creating a T cell-inflamed tumor microenvironment overcomes resistance to checkpoint blockade Haidong Tang, Yang Wang, Yang-Xin Fu K7 Biomarkers for treatment decisions? Reinhard Dummer K8 Combining oncolytic therapies in the era of checkpoint inhibitors Igor Puzanov K9 Immune checkpoint blockade for melanoma: should we combine or sequence ipilimumab and PD-1 antibody therapy? Michael A. Postow News in immunotherapy K10 An update on adjuvant and neoadjuvant therapy for melanom Ahmad Tarhini K11 Targeting multiple inhibitory receptors in melanoma Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sanders, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour K12 Improving adoptive immune therapy using genetically engineered T cells David F. Stroncek Tumor microenvironment and biomarkers K13 Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression? Veronica Huber, Licia Rivoltini K14 Update on the SITC biomarker taskforce: progress and challenges Magdalena Thurin World-wide immunoscore task force: an update K15 The immunoscore in colorectal cancer highlights the importance of digital scoring systems in surgical pathology Tilman Rau, Alessandro Lugli K16 The immunoscore: toward an integrated immunomonitoring from the diagnosis to the follow up of cancer’s patients Franck Pagès Economic sustainability of melanoma treatments: regulatory, health technology assessment and market access issues K17 Nivolumab, the regulatory experience in immunotherapy Jorge Camarero, Arantxa Sancho K18 Evidence to optimize access for immunotherapies Claudio Jommi ORAL PRESENTATIONS Molecular and immuno-advances O1 Ipilimumab treatment results in CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCs Yago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy Gentilcore, Isabel Poschke, Giuseppe V. Masucci, Johan Hansson, Rolf Kiessling O2 Evaluation of prognostic and therapeutic potential of COX-2 and PD-L1 in primary and metastatic melanoma Giosuè Scognamiglio, Francesco Sabbatino, Federica Zito Marino, Anna Maria Anniciello, Monica Cantile, Margherita Cerrone, Stefania Scala, Crescenzo D’alterio, Angela Ianaro, Giuseppe Cirino, Paolo Antonio Ascierto, Giuseppina Liguori, Gerardo Botti O3 Vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma: final overall survival results of the BRIM-3 study Paul B. Chapman, Caroline Robert, James Larkin, John B. Haanen, Antoni Ribas, David Hogg, Omid Hamid, Paolo Antonio Ascierto, Alessandro Testori, Paul Lorigan, Reinhard Dummer, Jeffrey A. Sosman, Keith T. Flaherty, Huibin Yue, Shelley Coleman, Ivor Caro, Axel Hauschild, Grant A. McArthur O4 Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma Mario Sznol, Margaret K. Callahan, Harriet Kluger, Michael A. Postow, RuthAnn Gordan, Neil H. Segal, Naiyer A. Rizvi, Alexander Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, Angel Rivera, Stephanie A. Kronenberg, Blessing Agunwamba, Mary Ruisi, Christine Horak, Joel Jiang, Jedd Wolchok Combination therapies O5 Efficacy and correlative biomarker analysis of the coBRIM study comparing cobimetinib (COBI) + vemurafenib (VEM) vs placebo (PBO) + VEM in advanced BRAF-mutated melanoma patients (pts) Paolo A. Ascierto, Grant A. McArthur, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stoyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Matthew Wongchenko, Ilsung Chang, Daniel O. Koralek, Isabelle Rooney, Yibing Yan, Antoni Ribas, Brigitte Dréno O6 Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600-mutant metastatic melanoma Ryan Sullivan, Omid Hamid, Manish Patel, Stephen Hodi, Rodabe Amaria, Peter Boasberg, Jeffrey Wallin, Xian He, Edward Cha, Nicole Richie, Marcus Ballinger, Patrick Hwu O7 Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma Thomas F. Gajewski, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Jason J. Luke, Ani S. Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Tara C. Gangadhar O8 Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma Reinhard Dummer, Georgina V. Long, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert H.I. Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J. Olszanski, Thomas F. Gajewski, John M. Kirkwood, Christine Gause, Lisa Chen, David R. Kaufman, Jeffrey Chou, F. Stephen Hodi News in immunotherapy O9 Two-year survival and safety update in patients (pts) with treatment-naïve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066 Victoria Atkinson, Paolo A. Ascierto, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Celeste Lebbé, Lars Ny, Matias Chacon, Paola Queirolo, Carmen Loquai, Parneet Cheema, Alfonso Berrocal, Karmele Mujika Eizmendi, Luis De La Cruz-Merino, Gil Bar-Sela, Christine Horak, Joel Jiang, Helene Hardy, Caroline Robert O10 Efficacy and safety of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL) who were treated beyond progression in CheckMate 066/067 Georgina V. Long, Jeffrey S. Weber, James Larkin, Victoria Atkinson, Jean-Jacques Grob, Reinhard Dummer, Caroline Robert, Ivan Marquez-Rodas, Catriona McNeil, Henrik Schmidt, Karen Briscoe, Jean-François Baurain, F. Stephen Hodi, Jedd D. Wolchok Tumor microenvironment and biomarkers O11 New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanoma Rosamaria Pinto, Simona De Summa, Vito Michele Garrisi, Sabino Strippoli, Amalia Azzariti, Gabriella Guida, Michele Guida, Stefania Tommasi O12 Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma and response to ipilimumab Nicolas Jacquelot, David Enot, Caroline Flament, Jonathan M. Pitt, Nadège Vimond, Carolin Blattner, Takahiro Yamazaki, Maria-Paula Roberti, Marie Vetizou, Romain Daillere, Vichnou Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L Slingluff Jr, Federica Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michaele Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander Eggermont, Laurence Zitvogel O13 Serum levels of PD1- and CD28-positive exosomes before Ipilimumab correlate with therapeutic response in metastatic melanoma patients Passarelli Anna, Tucci Marco, Stucci Stefania, Mannavola Francesco, Capone Mariaelena, Madonna Gabriele, Ascierto Paolo Antonio, Silvestris Franco O14 Immunological prognostic factors in stage III melanomas María Paula Roberti, Nicolas Jacquelot, David P Enot, Sylvie Rusakiewicz, Michaela Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Ana Carrizossa Anderson, Caroline Robert, Christophe Borg, Benjamin Weide, François Aubin, Stéphane Dalle, Michele Maio, Jedd D. Wolchok, Holbrook Kohrt, Maha Ayyoub, Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence Zitvogel POSTER PRESENTATIONS Molecular and immuno-advances P1 Human melanoma cells resistant to B-RAF and MEK inhibition exhibit mesenchymal-like features Anna Lisa De Presbiteris, Fabiola Gilda Cordaro, Rosa Camerlingo, Federica Fratangelo, Nicola Mozzillo, Giuseppe Pirozzi, Eduardo J. Patriarca, Paolo A. Ascierto, Emilia Caputo P2 Anti-proliferative and pro-apoptotic effect of ABT888 on melanoma cell lines and its potential role in the treatment of melanoma resistant to B-RAF inhibitors Federica Fratangelo, Rosa Camerlingo, Emilia Caputo, Maria Letizia Motti, Rosaria Falcone, Roberta Miceli, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Maria Vincenza Carriero, Giuseppe Pirozzi and Paolo Antonio Ascierto P3 Involvement of the L-cysteine/CSE/H2S pathway in human melanoma progression Elisabetta Panza, Paola De Cicco, Chiara Armogida, Giuseppe Ercolano, Rosa Camerlingo, Giuseppe Pirozzi, Giosuè Scognamiglio, Gerardo Botti, Giuseppe Cirino, Angela Ianaro P4 Cancer stem cell antigen revealing pattern of antibody variable region genes were defined by immunoglobulin repertoire analysis in patients with malignant melanoma Beatrix Kotlan, Gabriella Liszkay, Miri Blank, Timea Balatoni, Judit Olasz, Emil Farkas, Andras Szollar, Akos Savolt, Maria Godeny, Orsolya Csuka, Szabolcs Horvath, Klara Eles, Yehuda Shoenfeld and Miklos Kasler P5 Upregulation of Neuregulin-1 expression is a hallmark of adaptive response to BRAF/MEK inhibitors in melanoma Debora Malpicci, Luigi Fattore, Susan Costantini, Francesca Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto P6 HuR positively regulates migration of HTB63 melanoma cells Farnaz Moradi, Pontus Berglund, Karin Leandersson, Rickard Linnskog, Tommy Andersson, Chandra Prakash Prasad P7 Prolyl 4- (C-P4H) hydroxylases have opposing effects in malignant melanoma: implication in prognosis and therapy Cristiana Lo Nigro, Laura Lattanzio, Hexiao Wang, Charlotte Proby, Nelofer Syed, Marcella Occelli, Carolina Cauchi, Marco Merlano, Catherine Harwood, Alastair Thompson, Tim Crook P8 Urokinase receptor antagonists: novel agents for the treatment of melanoma Maria Letizia Motti, Katia Bifulco, Vincenzo Ingangi, Michele Minopoli, Concetta Ragone, Federica Fratangelo, Antonello Pessi, Gennaro Ciliberto, Paolo Antonio Ascierto, Maria Vincenza Carriero P9 Exosomes released by melanoma cell lines enhance chemotaxis of primary tumor cells Francesco Mannavola, Stella D’Oronzo, Claudia Felici, Marco Tucci, Antonio Doronzo, Franco Silvestris P10 New insights in mitochondrial metabolic reprogramming in melanoma Anna Ferretta, Gabriella Guida, Stefania Guida, Imma Maida, Tiziana Cocco, Sabino Strippoli, Stefania Tommasi, Amalia Azzariti, Michele Guida P11 Lenalidomide restrains the proliferation in melanoma cells through a negative regulation of their cell cycle Stella D’Oronzo, Anna Passarelli, Claudia Felici, Marco Tucci, Davide Quaresmini, Franco Silvestris Combination therapies P12 Chemoimmunotherapy elicits polyfunctional anti-tumor CD8 + T cells depending on the activation of an AKT pathway sustained by ICOS Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, MariaLaura Foddai, Helena Stabile, Angela Gismondi, Angela Santoni, Paola Nisticò P13 Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patients Andrea P. Sponghini, Francesca Platini, Elena Marra, David Rondonotti, Oscar Alabiso, Maria T. Fierro, Paola Savoia, Florian Stratica, Pietro Quaglino P14 Electrothermal bipolar vessel sealing system dissection reduces seroma output or time to drain removal following axillary and ilio-inguinal node dissection in melanoma patients: a pilot study Di Monta Gianluca, Caracò Corrado, Di Marzo Massimiliano, Marone Ugo, Di Cecilia Maria Luisa, Mozzillo Nicola News in immunotherapy P15 Clinical and immunological response to ipilimumab in a metastatic melanoma patient with HIV infection Francesco Sabbatino, Celeste Fusciello1, Antonio Marra, Rosario Guarrasi, Carlo Baldi, Rosa Russo, Di Giulio Giovanni, Vincenzo Faiola, Pio Zeppa, Stefano Pepe P16 Immunotherapy and hypophysitis: a case report Elisabetta Gambale, Consiglia Carella, Alessandra Di Paolo, Michele De Tursi Tumor microenvironment and biomarkers P17 New immuno- histochemical markers for the differential diagnosis of atypical melanocytic lesions with uncertain malignant potential Laura Marra, Giosuè Scognamiglio, Monica Cantile, Margherita Cerrone, Fara De Murtas, Valeria Sorrentino, Anna Maria Anniciello, Gerardo Botti P18 Utility of simultaneous measurement of three serum tumor markers in melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P19 The significance of various cut-off levels of melanoma inhibitory activity in evaluation of cutaneous melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P20 The long noncoding RNA HOTAIR is associated to metastatic progression of melanoma and it can be identified in the blood of patients with advanced disease Chiara Botti, Giosuè Scognamiglio, Laura Marra, Gabriella Aquino, Rosaria Falcone, Annamaria Anniciello, Paolo Antonio Ascierto, Gerardo Botti, Monica Cantile Other P21 The effect of Sentinel Lymph Node Biopsy in melanoma mortality: timing of dissection Cristina Fortes, Simona Mastroeni, Alessio Caggiati, Francesca Passarelli, Alba Zappalà, Maria Capuano, Riccardo Bono, Maurizio Nudo, Claudia Marino, Paola Michelozzi P22 Epidemiological survey on related psychopathology in melanoma Valeria De Biasio, Vincenzo C. Battarra IMMUNOTHERAPY BRIDGE KEYNOTE SPEAKER PRESENTATIONS Immunotherapy beyond melanoma K19 Predictor of response to radiation and immunotherapy Silvia Formenti K20 Response and resistance to PD-1 pathway blockade: clues from the tumor microenvironment Maria Libera Ascierto, Tracee L. McMiller, Alan E. Berger, Ludmila Danilova, Robert A. Anders, George J. Netto, Haiying Xu, Theresa S. Pritchard, Jinshui Fan, Chris Cheadle, Leslie Cope, Charles G. Drake, Drew M. Pardoll, Janis M. Taube and Suzanne L. Topalian K21 Combination immunotherapy with autologous stem cell transplantation, protein immunization, and PBMC reinfusion in myeloma patients Sacha Gnjatic, Sarah Nataraj, Naoko Imai, Adeeb Rahman, Achim A. Jungbluth, Linda Pan, Ralph Venhaus, Andrew Park, Frédéric F. Lehmann, Nikoletta Lendvai, Adam D. Cohen, and Hearn J. Cho K22 Anti-cancer immunity despite T cell “exhaustion” Speiser Daniel Immunotherapy in oncology (I-O): data from clinical trial K23 The Checkpoint Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) Vera Hirsh

Published
2016

25. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma

Author

Yanik, Elizabeth L., primary, Kaunitz, Genevieve J., additional, Cottrell, Tricia R., additional, Succaria, Farah, additional, McMiller, Tracee L., additional, Ascierto, Maria L., additional, Esandrio, Jessica, additional, Xu, Haiying, additional, Ogurtsova, Aleksandra, additional, Cornish, Toby, additional, Lipson, Evan J., additional, Topalian, Suzanne L., additional, Engels, Eric A., additional, and Taube, Janis M., additional

Published
2017
Full Text
View/download PDF

26. Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy

Author

Ascierto, Maria L., primary, Makohon-Moore, Alvin, additional, Lipson, Evan J., additional, Taube, Janis M., additional, McMiller, Tracee L., additional, Berger, Alan E., additional, Fan, Jinshui, additional, Kaunitz, Genevieve J., additional, Cottrell, Tricia R., additional, Kohutek, Zachary A., additional, Favorov, Alexander, additional, Makarov, Vladimir, additional, Riaz, Nadeem, additional, Chan, Timothy A., additional, Cope, Leslie, additional, Hruban, Ralph H., additional, Pardoll, Drew M., additional, Taylor, Barry S., additional, Solit, David B., additional, Iacobuzio-Donahue, Christine A., additional, and Topalian, Suzanne L., additional

Published
2017
Full Text
View/download PDF

27. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma

Author

Ascierto, Maria Libera, primary, McMiller, Tracee L., additional, Berger, Alan E., additional, Danilova, Ludmila, additional, Anders, Robert A., additional, Netto, George J., additional, Xu, Haiying, additional, Pritchard, Theresa S., additional, Fan, Jinshui, additional, Cheadle, Chris, additional, Cope, Leslie, additional, Drake, Charles G., additional, Pardoll, Drew M., additional, Taube, Janis M., additional, and Topalian, Suzanne L., additional

Published
2016
Full Text
View/download PDF

28. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

Author

Taube, Janis M., primary, Young, Geoffrey D., additional, McMiller, Tracee L., additional, Chen, Shuming, additional, Salas, January T., additional, Pritchard, Theresa S., additional, Xu, Haiying, additional, Meeker, Alan K., additional, Fan, Jinshui, additional, Cheadle, Chris, additional, Berger, Alan E., additional, Pardoll, Drew M., additional, and Topalian, Suzanne L., additional

Published
2015
Full Text
View/download PDF

29. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting

Author

Lipson, Evan J, primary, Sharfman, William H, additional, Chen, Shuming, additional, McMiller, Tracee L, additional, Pritchard, Theresa S, additional, Salas, January T, additional, Sartorius-Mergenthaler, Susan, additional, Freed, Irwin, additional, Ravi, Sowmya, additional, Wang, Hao, additional, Luber, Brandon, additional, Sproul, Janice Davis, additional, Taube, Janis M, additional, Pardoll, Drew M, additional, and Topalian, Suzanne L, additional

Published
2015
Full Text
View/download PDF

30. Safety and immunologic correlates of allogeneic melanoma GVAX (MelGVAX), a genetically engineered whole-cell melanoma vaccine.

Author

Lipson, Evan J., primary, Sharfman, William Howard, additional, Chen, Shuming, additional, McMiller, Tracee L., additional, Pritchard, Theresa Salay, additional, Salas, January T., additional, Sartorius-Mergenthaler, Susan, additional, Ravi, Sowmya, additional, Wang, Hao, additional, Taube, Janis M., additional, Pardoll, Drew M., additional, and Topalian, Suzanne Louise, additional

Published
2014
Full Text
View/download PDF

31. Structure-Based Design of Altered MHC Class II–Restricted Peptide Ligands with Heterogeneous Immunogenicity

Author

Chen, Shuming, primary, Li, Yili, additional, Depontieu, Florence R., additional, McMiller, Tracee L., additional, English, A. Michelle, additional, Shabanowitz, Jeffrey, additional, Kos, Ferdynand, additional, Sidney, John, additional, Sette, Alessandro, additional, Rosenberg, Steven A., additional, Hunt, Donald F., additional, Mariuzza, Roy A., additional, and Topalian, Suzanne L., additional

Published
2013
Full Text
View/download PDF

32. Abstract 446: Differential expression of immuno-regulatory genes associated with PD-L1 display: Implications for clinical blockade of the PD-1/PD-L1 pathway in melanoma.

Author

Young, Geoffrey D., primary, McMiller, Tracee L., additional, Xu, Haiying, additional, Chen, Shuming, additional, Berger, Alan E., additional, Fan, Jinshui, additional, Anders, Robert A., additional, Cheadle, Christopher, additional, Pardoll, Drew M., additional, Topalian, Suzanne L., additional, and Taube, Janis M., additional

Published
2013
Full Text
View/download PDF

33. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Author

Taube, Janis M., primary, Anders, Robert A., additional, Young, Geoffrey D., additional, Xu, Haiying, additional, Sharma, Rajni, additional, McMiller, Tracee L., additional, Chen, Shuming, additional, Klein, Alison P., additional, Pardoll, Drew M., additional, Topalian, Suzanne L., additional, and Chen, Lieping, additional

Published
2012
Full Text
View/download PDF

34. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Author

Brahmer, Julie R., primary, Drake, Charles G., additional, Wollner, Ira, additional, Powderly, John D., additional, Picus, Joel, additional, Sharfman, William H., additional, Stankevich, Elizabeth, additional, Pons, Alice, additional, Salay, Theresa M., additional, McMiller, Tracee L., additional, Gilson, Marta M., additional, Wang, Changyu, additional, Selby, Mark, additional, Taube, Janis M., additional, Anders, Robert, additional, Chen, Lieping, additional, Korman, Alan J., additional, Pardoll, Drew M., additional, Lowy, Israel, additional, and Topalian, Suzanne L., additional

Published
2010
Full Text
View/download PDF

37. Structure-Based Design of Altered MHC Class II-Restricted Peptide Ligands with Heterogeneous Immunogenicity.

Author

Shuming Chen, Yili Li, Depontieu, Florence R., McMiller, Tracee L., English, A. Michelle, Shabanowitz, Jeffrey, Kos, Ferdynand, Sidney, John, Sette, Alessandro, Rosenberg, Steven A., Hunt, Donald F., Mariuzza, Roy A., and Topalian, Suzanne L.

Subjects
*MELANOMA, *MAJOR histocompatibility complex, *LIGANDS (Biochemistry), *T cell receptors, *CD4 antigen, *VACCINATION
Abstract

Insights gained from characterizing MHC-peptide-TCR interactions have held the promise that directed structural modifications can have predictable functional consequences. The ability to manipulate T cell reactivity synthetically or through genetic engineering might thus be translated into new therapies for common diseases such as cancer and autoimmune disorders. In the current study, we determined the crystal structure of HLA-DR4 in complex with the nonmutated dominant gp100 epitope gp10044-59, associated with many melanomas. Altered peptide ligands (APLs) were designed to enhance MHC binding and hence T cell recognition of gp100 in HLA-DR4+ melanoma patients. IncreasedMHCbinding of several APLs was observed, validating this approach biochemically. Nevertheless, heterogeneous preferences of CD4+ T cells from several HLA-DR4+ melanoma patients for different gp100 APLs suggested highly variable TCR usage, even among six patients who had been vaccinated against the wild-type gp100 peptide. This heterogeneity prevented the selection of an APL candidate for developing an improved generic gp100 vaccine in melanoma. Our results are consistent with the idea that even conservative changes in MHC anchor residues may result in subtle, yet crucial, effects on peptide contacts with the TCR or on peptide dynamics, such that alterations intended to enhance immunogenicity may be unpredictable or counterproductive. They also underscore a critical knowledge gap that needs to be filled before structural and in vitro observations can be used reliably to devise new immunotherapies for cancer and other disorders. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

38. Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy.

Author

McMiller TL, Besharati S, Yarchoan M, Zhu Q, Ünsal-Kaçmaz K, Xu K, Lee J, Bhaijee F, Engle LL, Taube JM, Berger AE, Anders RA, and Topalian SL

Subjects
Humans, Male, Female, Middle Aged, Aged, Adult, Tumor Microenvironment immunology, Stomach Neoplasms immunology, Stomach Neoplasms virology, Stomach Neoplasms genetics, Herpesvirus 4, Human, Epstein-Barr Virus Infections immunology, Epstein-Barr Virus Infections complications, Epstein-Barr Virus Infections virology, Immunotherapy methods
Abstract

Background: Gastric carcinomas (GC) are aggressive malignancies, and only ~15% of patients respond to anti-programmed cell death (ligand) 1 (PD-(L)1) monotherapy. However, Epstein-Barr virus (EBV)-associated GCs (~5-10% of GCs) often harbor PD-L1 and PD-L2 chromosomal amplifications and robust CD8+ T cell infiltrates, and respond at a high rate to anti-PD-1. The current study compares the tumor immune microenvironments (TiMEs) of EBV+ versus EBV(-) GCs., Methods: Over 1000 cases of primary invasive GCs were screened to identify 25 treatment-naïve specimens for study (11 EBV+, 14 EBV(-)). Quantitative immunohistochemistry (IHC) was conducted for markers of immune cell subsets and co-regulatory molecules. Gene expression profiling (GEP) was performed on RNAs isolated from macrodissected areas of CD3+ T cell infiltrates abutting PD-L1+ stromal/tumor cells, using multiplex quantitative reverse transcriptase PCR for a panel of 122 candidate immune-related genes., Results: IHC revealed that 17/25 GCs contained PD-L1+ stromal cells, with no significant difference between EBV+/- specimens; however, only 3/25 specimens (all EBV+) contained PD-L1+ tumor cells. CD8+ T cell densities were higher in EBV+ versus EBV(-) tumors (p=0.044). With GEP normalized to the pan-leukocyte marker PTPRC/ CD45, EBV+ GCs overexpressed ITGAE (CD103, marking intraepithelial T cells and a dendritic cell subset) and the interferon-inducible genes CXCL9 and IDO1 . In contrast, EBV(-) tumors overexpressed several functionally-related gene groups associated with myeloid cells ( CD163 , IL1A , NOS2, RIGI), immunosuppressive cytokines/chemokines ( CXCL2 , CXCR4 , IL10, IL32), coinhibitory molecules ( HAVCR2/ TIM-3 and VSIR/ VISTA), and adenosine pathway components ( ENTPD1/ CD39 and NT5E/ CD73). Notably, compared with EBV+ GCs, EBV(-) GCs also overexpressed components of the cyclooxygenase 2 (COX-2)/prostaglandin E2 (PGE2) pathway associated with cancer-promoting inflammation, including PTGS2/ COX-2 (most highly upregulated gene, 32-fold, p=0.005); prostaglandin receptors PTGER1 (EP1; up 21-fold, p=0.015) and PTGER4 (EP4; up twofold, p=0.022); and the major COX-2-inducing cytokine IL1B (up 11-fold, p=0.019). Consistent with these findings, COX-2 protein expression trended higher in EBV(-) versus EBV+ GCs (p=0.068)., Conclusions: While certain markers of immunosuppression are found in the GC TiME regardless of EBV status, EBV(-) GCs, which are much more common than EBV+ GCs, overexpress components of the COX-2/PGE2 pathway. These findings provide novel insights into the immune microenvironments of EBV+ and EBV(-) GC, and offer potential targets to overcome resistance to anti-PD-(L)1 therapies., Competing Interests: Competing interests: MY receives grant/research support (to Johns Hopkins University) from Bristol Myers Squibb, Exelixis, Incyte, and Genentech; receives honoraria and consulting fees from Genentech, Incyte, Exelixis, AstraZeneca, Replimune, Hepion, and Lantheus; is a cofounder with equity in Adventris Pharmaceuticals and has patents related to cancer vaccines, outside of the submitted work. KU-K has received stock from Bristol Myers Squibb, Pfizer, and BioNTech. KX has received stock from Bristol Myers Squibb. JMT receives consulting fees from Bristol Myers Squibb, Merck & Co, AstraZeneca, Elephas, Regeneron, Roche, Compugen, and Akoya Biosciences; has patents related to the AstroPath imaging suite; has received institutional research grants from Bristol Myers Squibb and Akoya Biosciences; and has received equipment and stock from Akoya Biosciences. RAA reports grants from RAPT Therapeutics, and personal fees from Bristol Myers Squibb, AstraZeneca, Merck, and JAZZ Oncology. SLT receives consulting fees from Bristol Myers Squibb, Dragonfly Therapeutics, PathAI, and (spouse) Amgen, Compugen, Janssen Pharmaceuticals, Normunity, RAPT Therapeutics, Regeneron, Takeda Pharmaceuticals, and Tizona LLC; receives research grants from Bristol Myers Squibb, and (spouse) Compugen and Immunomic Therapeutics; has stock options or stock in Atengen Inc., Dragonfly Therapeutics, and (spouse) DNAtrix, Dracen, ManaT Bio, RAPT Therapeutics, and Tizona LLC; and has patents related to the treatment of MSI-high cancers with anti-PD-1 and (spouse) related to T-cell regulatory molecules including LAG-3. The following authors declare no potential conflicts of interest: SB, TLM, QZ, JL, FB, LLE, and AEB., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results